Calciferol inj. 300,000IU (Cholecalciferol)
Product classification: General medication
Cholecalciferol in 1ml …………………………………………………..7.5mg/ml(비타민D₃ 3000,000 I.U)
Injections contained yellow cholecalciferol fluid that is visible colorless to green stored in brown glass ampoules
Prevention and treatment of vitamin D deficiency in adults at high risk of absorption disorder of vitamin D
Use it according to the doctor's prescription, and check 25(OH)-vitamin D level in the blood
Do not exceed the required dose as the adverse reaction increases with an overdose.
Adults: Intramuscular injection of 300,000IU of cholecalciferol.
Annual dose of cholecalciferol is to be kept within 600,000 IU.
1mL/ampule X 10ampoule
Avoid direct sunlight and store it in a sealed container at room temperature (1~30℃)
1) If treatments containing vitamin D and foods fortified with vitamin D are given to patients at the same time in order to avoid overdose, the total amount of vitamind D should take into account.
2) Observe calcium concentrations and stop administration if serum calcium exceeds 10.5 mg/dl or urinary calcium exceeds 4 mg/kg/day in adults.
3) If calcium intake is high, monitor calcium concentration in blood and urine regularly.
2. Do not administer to the next patient.
1) A patient who is hypersensitive to the composition of this drug
2) A patient with hypercalcemia and hypercalciuria
3) A patient with calcium stone
4) Patients with history of kidney calcium stone or at risk of developing stones
5) A patient with nephropathy
6) A patient who is an immovable on the sickbed
7) A patient with sarcoidosis
8) A patient with pseudo-hypoparathyroidism
9) Pregnant and lactating women
3. Abnormal reaction
1) Administration of cholecalciferol can cause the following abnormal reactions.
Headaches, asthenia, fatigue, muscle pain, loss of appetite, weight loss, poor growth, nausea, vomiting, constipation, diarrhea, hyperuria and polydipsia, dehydration, hypertension, calcium stone, kidney and tissue calcification, kidney failure, excess bone calcification, arrhythmia, perceptual disorders, joint pain, myasthenia, drowsiness, azotemia, allergic reaction (hypersensitivity), thirst, confusion, tympanosis, sotmachache, metallic taste, mouth dryness, rash, pruritus can be develope
4. Normal precautions
1) In the clinical trial, after patients with vitamin D deficiency were given cholecalciferol and their blood were tested for 25(OH) vitamin D and parathyroid hormone levels.
2) Patients with vitamin D deficiency (typically less than 10 ng/ml of 25(OH) vitamin D concentration in the blood) should be monitored when administering this drug as abnormal reactions are increased due to excessive dosage.
3) Measure and check serum creatinine level every 3-6 months. In particular, elderly people and patients who administer cardiac glycoside in conjunction with diuretic are regularly monitored for serum creatinine levels. In case of renal dysfunctions, dose is reduced appropriately or stopped in accordance with the patient's condition.
4) Patients who have problems with nephritic excretion of calcium and phosphoric acid monitor calcium concentrations in the blood and urine.
1) Antiseizure drug such as phenytoin, barbiturates, and glucocorticoid can affect the functioning of vitamin D.
2) Cholestyramine, colestipol and orlistat can reduce the absorption of vitamin D, and reduce the retention of vitamin D in the liver in the case of chronic alcoholism
3) Thiazide diuretics can reduce calcium excretion in the kidneys, leading to hypercalcemia. Thus, calcium concentration in blood and urine should be monitored during prolonged treatment.
4) During vitamin D administration, arrhythmia can be developed and the toxicity of the cardiac glycoside increases as calcium concentrations are increased. These patients should measure ECGs and monitor calcium concentrations in blood and urine.
5) Aluminium-containing antacids can reduce the absorption of vitamin D, which can impair the efficacy of this drug, and magnesium-containing drugs can cause hypermagnesaemia.
6) In animal testing, the function of warfarin was increased when calciferol and wafarin were administered together. Be careful when administrating this medicine with warfarin together.
6. Administration to pregnant and lactating women
1) Animal study has not been conducted into teratogenic test.
2) Do not administer excess vitamin D during pregnancy. Prolonged hypercalcemia can cause physical and psychological retardation, supravalvular-aortic stenosis, and retinopathy in children. Therefore, this drug is not used for pregnant or lactating women.
7. Administration to children
Safety and effectiveness for children are not established.
8. Treatment when overdose
1) When overdose on this drug, stop administrating vitamin D and reduce calcium intake. Furthermore, increase diuresis and increase water intake.
2) Hemodialysis can be carried out with a calcium-free dialysate in case of hypouresis.
3) There is no particularly known antidote.
4) Patients administered high-doses for long period are informed of the symptoms of overdose in advance.
9. Application precautions
1) Don't take this medicine in conjunction with any other medication.
2) Use the ampoule quickly after opening and discard the residue.
10. Precautions for storage and handling
1) Avoid direct sunlight and store at 1~30℃.